SAB Bio appoints David Zaccardelli as Chair and Rita Jain as independent director

SAB Biotherapeutics, Inc.

David Zaccardelli, Pharm.D., appointed Chair of the Board effective January 5, 2026; led Ohtuvayre launch at Verona Pharma.
Rita Jain, M.D., appointed independent director; brings autoimmune/inflammatory disease drug development expertise.
Appointments follow RA Capital's nomination rights from July 2025 private placement; CEO Samuel Reich remains on board.
Company advancing SAB-142, a fully human anti-thymocyte immunoglobulin for type 1 diabetes and autoimmune diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.